The largest blog for reading the latest medical research on all disease, the prevention and its treatment . Pulled from variety of sources

Friday, August 26, 2016

When DNA and medical tests disagree about breast cancer risk, which to believe? : foxnews





as declared in foxnews

When DNA and medical tests disagree about breast cancer risk, which to believe?

When DNA and medical tests disagree about breast cancer risk, which to believe?
When DNA and medical tests disagree about breast cancer risk, which to believe?
It's a dilemma more and more cancer patients will face as genetic testing becomes part of everyday health care: When a DNA test indicates low risk of a tumor spreading, but traditional tests show a high risk, which do you believe?According to a large European study of 6,693 patients published on Wednesday, many women with early breast cancer can safely believe the genetic test.Patients who skipped chemotherapy when a genetic test showed low risk of the cancer advancing but a traditional test suggested high risk were almost as likely to survive five years without the cancer recurring as those who had chemo.(The traditional tests look for cancer cells in lymph nodes and fast-dividing cells, for instance, and include demographic facts of life, such as being over 50.)


as well news-medical

Genetic test may be able to predict need for chemotherapy in early-stage breast cancer

Genetic test may be able to predict need for chemotherapy in early-stage breast cancer
Genetic test may be able to predict need for chemotherapy in early-stage breast cancer
By Sally Robertson, BScPatients with early stage breast cancer who have a low genetic risk of disease recurrence may not need to have chemotherapy, report researchers.The findings come from a study that used a genetic test called MammaPrint to assess the risk of cancer recurrence in women with early-stage disease.The genetic markers that tumors carry vary from individual to individual and MammaPrint works by checking a 70-gene signature that predicts the likelihood of disease recurrence among such patients.As reported in the New England Journal of Medicine, Laura van't Veer (San Francisco Helen Diller Family Comprehensive Cancer Center) and colleagues used MammaPrint to genetically profile excised tumors from almost 6,700 patients with early-stage breast cancer.


in addition mirror

Stephanie Davis does live breast cancer exam as former X Factor star Brenda Edwards reveals she been give "all clear"

Stephanie Davis does live breast cancer exam as former X Factor star Brenda Edwards reveals she been give "all clear"
Stephanie Davis does live breast cancer exam as former X Factor star Brenda Edwards reveals she been give
Please refresh this page in your browser to reload this live event videoThe Live Event you are trying to watch is either unavailable or has not started Please refresh this page in your browser to reload this live event videoStephanie Davis took part in a live breast exam on Loose Women as she spoke with breast cancer survivor Brenda Edwards.The 23-year-old actress who had her first stint as a guest panelist on the ITV daytime show wanted to encourage other young women how to correctly check their breasts for lumps.Brenda, who had been diagnosed with stage three breast cancer and had recently had a mastectomy, explained how she discovered a lump after checking her boobs when a friend had been diagnosed.A pregnant Steph asked: "I don't really search my breasts.


besides ktoo

Study of breast cancer treatment reveals paradox of precision medicine

Study of breast cancer treatment reveals paradox of precision medicine
Study of breast cancer treatment reveals paradox of precision medicine
A major study about the best way to treat early-stage breast cancer reveals that "precision medicine" doesn't provide unambiguous answers about how to choose the best therapy."Precision doesn't mean certainty," says David Hunter, a professor of cancer prevention at Harvard's T.H.Chan School of Public Health.That point is illustrated in a large study published Wednesday in the New England Journal of Medicine, involving decisions about chemotherapy.


No comments:

Post a Comment